Affinage

CDCA7

Cell division cycle-associated protein 7 · UniProt Q9BWT1

Length
371 aa
Mass
42.6 kDa
Annotated
2026-04-28
37 papers in source corpus 19 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDCA7 is the DNA-recognition subunit of a bipartite chromatin remodeling complex with the SNF2-family ATPase HELLS, essential for maintenance DNA methylation at pericentromeric heterochromatin and other repetitive elements. Its conserved C-terminal 4CXXC zinc-finger domain senses hemimethylated CpG dinucleotides within nucleosomal DNA, recruits HELLS to chromatin, and activates HELLS ATPase and nucleosome sliding activities to enable UHRF1/DNMT1-mediated methylation maintenance; ICF syndrome type 3 mutations in this domain abolish DNA binding and chromatin remodeling (PMID:29339483, PMID:39178260, PMID:39142653). Beyond epigenetic maintenance, CDCA7 facilitates classical non-homologous end joining through interaction with Ku70/Ku80 and suppresses R-loop accumulation at pericentromeric repeats (PMID:30307408, PMID:33082427). CDCA7 is transcriptionally regulated by c-MYC, E2F1, Notch1, and ZBTB24, and its nuclear localization is controlled by AKT-mediated phosphorylation at Thr163, which promotes 14-3-3 binding and cytoplasmic sequestration (PMID:23166294, PMID:11598121, PMID:16580749, PMID:27466202).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2001 Medium

    Identifying CDCA7 as a direct c-MYC transcriptional target that could complement a transformation-defective MYC mutant established the gene's entry into the MYC-driven proliferation network.

    Evidence Representational difference analysis with inducible MYC plus Rat1a transformation complementation assay

    PMID:11598121

    Open questions at the time
    • Mechanism by which CDCA7 complements Myc Box II deletion unknown
    • No endogenous CDCA7 functional assay beyond transformation
  2. 2006 Medium

    Showing that E2F1 directly activates CDCA7 transcription and that the C-terminal cysteine-rich region possesses transcriptional activator activity placed CDCA7 at the intersection of MYC and Rb/E2F pathways and hinted at a dual role as both a target and effector of transcription.

    Evidence ChIP for E2F binding at CDCA7 promoter, promoter-reporter assays, mammalian one-hybrid

    PMID:16580749

    Open questions at the time
    • Endogenous transcriptional targets of CDCA7 not identified
    • Relevance of intrinsic transcriptional activity to physiological function unclear
  3. 2012 High

    Demonstrating that AKT phosphorylates CDCA7 at Thr163, causing 14-3-3 binding and cytoplasmic sequestration away from MYC, revealed a signaling-dependent switch controlling CDCA7 nuclear function and MYC-dependent apoptosis.

    Evidence In vitro AKT kinase assay, co-immunoprecipitation with MYC and 14-3-3, subcellular fractionation, Rat1a apoptosis and transformation assays

    PMID:23166294

    Open questions at the time
    • Whether AKT-CDCA7 axis operates in chromatin remodeling context not tested
    • Phosphorylation-deficient knock-in models lacking
  4. 2014 Medium

    Identification of CDCA7 as a Notch1/RBPj target in the AGM region whose loss impairs hematopoietic stem cell emergence in zebrafish broadened CDCA7's role from cancer biology to developmental hematopoiesis.

    Evidence ChIP-on-chip for RBPj, ChIP for Notch1 at CDCA7 promoter, AGM knockdown cultures, zebrafish loss-of-function

    PMID:25385755

    Open questions at the time
    • Mechanism of CDCA7 action in HSC emergence not determined
    • Whether chromatin remodeling function is involved in this context unknown
  5. 2016 High

    Establishing that ZBTB24 directly controls CDCA7 transcription—and that ICF2-patient ZBTB24 mutations reduce CDCA7 levels—created a transcriptional hierarchy linking four ICF syndrome genes (ZBTB24→CDCA7→HELLS→DNMT3B pathway).

    Evidence Zbtb24 BTB-domain deletion mouse, transcriptome analysis, ChIP at CDCA7 promoter, patient sample validation

    PMID:27466202

    Open questions at the time
    • Whether ZBTB24 regulation of CDCA7 is tissue-specific not fully resolved
    • Other transcriptional targets of ZBTB24 that contribute to ICF not excluded
  6. 2018 High

    Reconstituting the CDCA7–HELLS nucleosome remodeling complex answered a central question: HELLS alone lacks remodeling activity, and CDCA7 serves as its obligate activator, with ICF3 mutations abolishing HELLS chromatin recruitment.

    Evidence Reconstituted nucleosome remodeling assay in Xenopus egg extracts, proteomic chromatin profiling

    PMID:29339483

    Open questions at the time
    • Structural basis of CDCA7-HELLS interaction not determined at this point
    • How the complex interfaces with DNMT1/UHRF1 not shown
  7. 2018 High

    Demonstrating that CDCA7 interacts with Ku70/Ku80 and is required for classical NHEJ extended the complex's function beyond methylation maintenance to DNA double-strand break repair.

    Evidence Co-immunoprecipitation (nuclease-sensitive), C-NHEJ reporter assay, live-cell imaging of Ku80 recruitment, ICF patient lymphoblastoid cells

    PMID:30307408

    Open questions at the time
    • Whether HELLS is required for the NHEJ function or CDCA7 acts independently unclear
    • Direct structural basis of CDCA7-Ku interaction not resolved
  8. 2019 Medium

    Finding that CDCA7 knockdown disrupts actomyosin and tubulin cytoskeleton polarization in lymphoma cells, rescuable by ROCK/myosin II inhibitors, uncovered an unexpected link to cell migration upstream of the actomyosin axis.

    Evidence Matrigel invasion assay, zebrafish xenograft, phalloidin/tubulin staining, inhibitor rescue

    PMID:31221787

    Open questions at the time
    • Direct molecular target linking CDCA7 to cytoskeletal regulation not identified
    • Whether this reflects an epigenetic or non-epigenetic function unknown
  9. 2020 Medium

    Showing that CDCA7/HELLS is required for DNMT1/UHRF1 accumulation on nascent DNA and that its loss causes pericentromeric R-loop accumulation (rescuable by RNASEH1) mechanistically connected the remodeling complex to the replication-coupled methylation machinery and genome stability.

    Evidence iPOND, R-loop detection assays, RNASEH1 rescue in ICF mutant cells

    PMID:33082427

    Open questions at the time
    • Whether R-loop suppression is a direct or indirect consequence of chromatin remodeling not resolved
    • Single lab finding
  10. 2024 High

    Cryo-EM and crystal structures of the CDCA7 zinc-finger domain bound to nucleosomal DNA resolved the molecular basis of hemimethylated CpG recognition, showing how CDCA7 reads methylation status in the DNA major groove and how ICF mutations disrupt this sensing.

    Evidence Cryo-EM of CDCA7–nucleosome complex, crystal structure of CRD, in vitro binding assays with hemimethylated DNA, ICF mutant analysis, UHRF1 ubiquitylation assay

    PMID:39142653 PMID:39178260 PMID:39178265

    Open questions at the time
    • Full structure of CDCA7–HELLS–nucleosome ternary complex not yet available
    • Mechanism by which CDCA7 N-terminal region inhibits ATPase activity structurally unresolved
  11. 2024 Medium

    An in vivo knock-in mouse with a pathogenic Cdca7 variant demonstrated that CDCA7-dependent DNA methylation controls clustered protocadherin isoform choice in the brain, broadening the physiological scope of the CDCA7-HELLS axis to neuronal gene regulation.

    Evidence Knock-in mouse, WGBS, ChIP-seq for H3K4me3/H3K9me3/CTCF, RNA-seq

    PMID:38335290

    Open questions at the time
    • Functional consequences for neuronal connectivity or behavior not assessed
    • Whether HELLS is equally required at protocadherin loci not tested
  12. 2025 Medium

    Discovery that the ZBTB24–CDCA7–HELLS axis maintains DNA methylation at the Dux cluster to suppress 2C-like reprogramming in ESCs revealed a role for CDCA7 in totipotency regulation, rescuable by site-specific re-methylation.

    Evidence CDCA7 KO mESCs, ChIP, site-specific re-methylation rescue, transcriptomics

    PMID:40226918

    Open questions at the time
    • In vivo relevance during preimplantation development not tested
    • Whether CDCA7 loss affects other totipotency regulators beyond Dux unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key open questions include: the full structural architecture of the CDCA7–HELLS–nucleosome ternary complex, whether CDCA7's NHEJ and cytoskeletal roles depend on HELLS or represent independent functions, how AKT-mediated phosphorylation integrates with chromatin remodeling activity, and the in vivo consequences of CDCA7 loss beyond ICF syndrome (neuronal, hematopoietic, totipotency phenotypes).
  • No ternary complex structure
  • HELLS-independent vs HELLS-dependent functions not delineated
  • In vivo tissue-specific conditional knockout phenotypes not systematically characterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 3 GO:0098772 molecular function regulator activity 2
Localization
GO:0005694 chromosome 3 GO:0005634 nucleus 2
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1643685 Disease 3 R-HSA-1640170 Cell Cycle 2 R-HSA-73894 DNA Repair 1
Partners
HELLSMYCUHRF1XRCC5XRCC6YWHAZZBTB24
Complex memberships
CDCA7-HELLS nucleosome remodeling complex

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 CDCA7 and HELLS form a stoichiometric bipartite nucleosome remodeling complex on chromatin; HELLS alone lacks remodeling activity but the CDCA7-HELLS complex possesses nucleosome remodeling activity. CDCA7 is essential for loading HELLS onto chromatin, and ICF patient mutations in CDCA7 abolish this recruitment. Reconstituted nucleosome remodeling assay in Xenopus egg extracts, proteomic chromatin profiling, Aurora B sensitivity assay Proceedings of the National Academy of Sciences of the United States of America High 29339483
2024 The C-terminal zinc-finger domain of CDCA7 (zf-4CXXC_R1 / HMZF domain) is an evolutionarily conserved hemimethylated CpG sensor. Cryo-EM structural analysis of the CDCA7-nucleosome complex shows the domain recognizes hemimethylated CpG in the outward-facing DNA major groove within the nucleosome core particle; ICF disease mutations eliminate this binding. CDCA7 recruits HELLS to hemimethylated chromatin and facilitates UHRF1-mediated H3 ubiquitylation associated with replication-uncoupled maintenance DNA methylation. Cryo-EM structure of CDCA7-nucleosome complex, in vitro hemimethylated DNA binding assay, ICF mutant functional analysis, UHRF1 ubiquitylation assay Science advances High 39178260
2024 The CDCA7 C-terminal cysteine-rich domain (CRD) adopts a unique zinc-binding structure that recognizes a CpG dyad in a non-B DNA structure with strand-specific CpG hemi-methylation. ICF mutants fail to bind this non-B DNA. At S phase, CDCA7 concentrates in constitutive heterochromatin foci in a CRD-dependent manner. Crystal/structural analysis of CRD, in vitro DNA-binding assays, ICF mutant analysis, live-cell imaging of heterochromatin foci Science advances High 39178265
2024 The central region of CDCA7 is critical for binding to HELLS and for activating HELLS ATPase and nucleosome sliding activities; the N-terminal region inhibits ATPase activity; the C-terminal 4CXXC zinc finger domain confers preference for hemimethylated CpG DNA in HELLS-CDCA7 ATPase activity. CDCA7 and HELLS show replication-dependent pericentromeric heterochromatin foci formation in mouse ES cells, lost with ICF zinc finger mutations. Domain deletion/mutation analysis, in vitro ATPase assays, nucleosome sliding assays, live-cell imaging of HELLS-CDCA7 foci in mESCs Nucleic acids research High 39142653
2018 CDCA7 co-immunoprecipitates with C-NHEJ proteins Ku80 and Ku70 (interaction sensitive to nuclease treatment and abrogated by ICF3 mutation impairing chromatin binding). CDCA7- and HELLS-deficient HEK293 cells display compromised C-NHEJ activity, delayed Ku80 accumulation at DNA damage sites, increased γH2AX, aneuploidy, and centrosome amplification. CDCA7 and HELLS are also required for CG methylation maintenance at centromeric/pericentromeric repeats. Co-immunoprecipitation, C-NHEJ reporter assay, live-cell imaging of Ku80 recruitment at damage sites, ICF patient lymphoblastoid cell analysis The Journal of clinical investigation High 30307408
2012 AKT phosphorylates CDCA7 at threonine 163, promoting CDCA7 binding to 14-3-3, dissociation from MYC, and cytoplasmic sequestration. CDCA7 associates with MYC in a phosphorylation-dependent manner. Upon serum withdrawal, CDCA7 expression in the presence of MYC sensitizes cells to apoptosis; CDCA7 knockdown reduces MYC-dependent apoptosis. MYC-induced transformation of fibroblasts is reduced by CDCA7 co-expression. In vitro kinase assay (AKT phosphorylation of CDCA7), co-immunoprecipitation, 14-3-3 binding assay, apoptosis assay, Rat1a transformation assay, subcellular fractionation Molecular and cellular biology High 23166294
2001 JPO1/CDCA7 is a direct c-Myc transcriptional target. CDCA7 overexpression complements a transformation-defective Myc Box II mutant in the Rat1a transformation assay, indicating a genetic link between c-Myc and CDCA7. CDCA7 is a nuclear 47-kDa protein. Representational difference analysis, inducible Myc system, Rat1a transformation assay, subcellular localization The Journal of biological chemistry Medium 11598121
2006 CDCA7 is a direct transcriptional target of E2F1 (and E2F2/E2F4); an E2F-responsive element in the CDCA7 promoter is required for E2F1-induced activation. The C-terminal cysteine-rich region of CDCA7 possesses intrinsic transcriptional activator activity in a mammalian one-hybrid assay. Adenoviral E2F1 overexpression, promoter-reporter constructs, ChIP, mammalian one-hybrid assay Biochimica et biophysica acta Medium 16580749
2016 ZBTB24 directly controls Cdca7 expression: ZBTB24 is enriched at the CDCA7 promoter by ChIP and loss of Zbtb24 causes Cdca7 to be the top down-regulated gene in mESCs; CDCA7 levels are reduced in ICF2 patients carrying ZBTB24 nonsense mutations. This establishes a transcriptional hierarchy where ZBTB24 acts upstream of CDCA7. Zbtb24 BTB-domain deletion mouse, transcriptome analysis, ChIP at CDCA7 promoter, rescue by ectopic ZBTB24 expression, patient sample analysis Human molecular genetics High 27466202
2020 The CDCA7/HELLS chromatin remodeling complex is required for accumulation of the DNMT1/UHRF1 maintenance DNA methylation complex on nascent DNA. Loss of this complex leads to increased transcription and aberrant DNA:RNA hybrid (R-loop) formation at pericentromeric repeats; ectopic RNASEH1 expression reduces DNA damage accumulation in ICF mutant cells, linking the complex to R-loop resolution/prevention. iPOND (isolation of proteins on nascent DNA), R-loop detection assays, RNASEH1 rescue experiment in ICF mutant cells Scientific reports Medium 33082427
2014 Cdca7 is a direct transcriptional target of Notch1/RBPj in the aorta-gonad-mesonephros (AGM) region; ChIP-on-chip identified the Cdca7 promoter as enriched for RBPj and Notch1. CDCA7 knockdown in AGM cells induces hematopoietic differentiation and loss of progenitor population; loss-of-function in zebrafish impairs hematopoietic stem cell emergence. ChIP-on-chip (RBPj), ChIP (Notch1), Cdca7 knockdown in AGM cultures, zebrafish loss-of-function The Journal of experimental medicine Medium 25385755
2019 CDCA7 is required for lymphoma cell migration and invasion; its knockdown disrupts actomyosin and tubulin cytoskeleton polarization, increases filamentous actin, and induces myosin activation. Inhibitors of actin polymerization, myosin II, or ROCK restore migration capacity of CDCA7-silenced cells, placing CDCA7 upstream of the actomyosin cytoskeleton in lymphoma cell motility. Matrigel invasion assay, mouse xenograft, zebrafish invasion model, phalloidin/tubulin staining, inhibitor rescue (ROCK, myosin II, actin polymerization) Haematologica Medium 31221787
2025 The ZBTB24-CDCA7-HELLS axis maintains DNA methylation at the Dux cluster in mouse ESCs, suppressing 2C-like reprogramming. Disruption of CDCA7 causes Dux hypomethylation and derepression; CDCA7 is enriched at the Dux cluster by ChIP and recruits the CDCA7-HELLS complex to constitutive heterochromatin. Site-specific re-methylation at the Dux promoter reverses the 2C-like state. CDCA7 KO mESCs, ChIP, site-specific re-methylation rescue, transcriptomic analysis of 2C gene activation Nucleic acids research Medium 40226918
2021 CDCA7 directly binds the CCNA2 (Cyclin A2) promoter and promotes its expression, thereby facilitating cell cycle progression in esophageal squamous cell carcinoma; knockdown of CCNA2 reverses the malignant phenotype induced by CDCA7 overexpression. ChIP, luciferase reporter assay, rescue assay with CCNA2 knockdown Frontiers in oncology Medium 34737951
2019 ZBTB24-deficiency promotes TRAIL-induced apoptosis in T cells via downregulation of CDCA7; CDCA7 knockdown phenocopies ZBTB24 depletion, and CDCA7 overexpression rescues apoptosis in ZBTB24-depleted Jurkat T cells, placing CDCA7 downstream of ZBTB24 in the TRAIL-receptor apoptosis pathway. Genetic epistasis (rescue of ZBTB24 KD by CDCA7 overexpression), apoptosis assays, TRAIL-R blocking experiments Biochemical and biophysical research communications Medium 31030944
2024 CDCA7 acts as a transcriptional repressor and epigenetic regulator of clustered protocadherin isoform choice in the brain in vivo; a pathogenic Cdca7 missense variant leads to aberrant DNA hypomethylation in B genomic compartment domains, increased protocadherin isoform expression, gain of H3K4me3, and increased CTCF binding, without affecting H3K9me3 deposition. Knock-in mouse with pathogenic Cdca7 missense variant, whole-genome bisulfite sequencing, ChIP-seq (H3K9me3, H3K4me3, CTCF), RNA-seq across tissues Science advances Medium 38335290
2025 CDCA7 transcriptionally activates autophagy-related genes ULK1, ATG2A, and ATG3 by directly binding their promoters (identified by ChIP-seq), thereby promoting autophagic flux and chemoresistance in breast cancer drug-tolerant persister cells. ChIP-seq, dual-luciferase assay, site-directed mutagenesis, electron microscopy, mRFP-GFP-LC3 autophagic flux assay Frontiers in immunology Medium 41890763
2025 CDCA7 interacts with STAT3 protein (by immunoprecipitation) and enhances STAT3-dependent transcriptional regulation of hexokinase 2, promoting aerobic glycolysis and gemcitabine resistance in pancreatic cancer cells. Co-immunoprecipitation, transcriptional reporter assay, glycolysis functional assay Cell death & disease Low 39905019
2024 METTL3 enhances stability of CDCA7 mRNA through m6A methylation, as validated by methylated RNA immunoprecipitation (MeRIP). MeRIP assay, RBPsuite prediction followed by experimental validation Pathology, research and practice Low 38959625

Source papers

Stage 0 corpus · 37 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Mutations in CDCA7 and HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome. Nature communications 149 26216346
2018 HELLS and CDCA7 comprise a bipartite nucleosome remodeling complex defective in ICF syndrome. Proceedings of the National Academy of Sciences of the United States of America 106 29339483
2018 CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome. The Journal of clinical investigation 73 30307408
2019 Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDCA7 via sponging miR-302e. In vitro cellular & developmental biology. Animal 64 31332696
2018 Comparative methylome analysis of ICF patients identifies heterochromatin loci that require ZBTB24, CDCA7 and HELLS for their methylated state. Human molecular genetics 63 29659838
2012 The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation. Molecular and cellular biology 60 23166294
2005 The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer research 56 15994934
2001 A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. The Journal of biological chemistry 54 11598121
2016 Converging disease genes in ICF syndrome: ZBTB24 controls expression of CDCA7 in mammals. Human molecular genetics 51 27466202
2014 Identification of Cdca7 as a novel Notch transcriptional target involved in hematopoietic stem cell emergence. The Journal of experimental medicine 42 25385755
2006 JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity. Biochimica et biophysica acta 37 16580749
2020 CDCA7 and HELLS suppress DNA:RNA hybrid-associated DNA damage at pericentromeric repeats. Scientific reports 33 33082427
2019 CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle. Pathology, research and practice 25 31570276
2024 CDCA7 is an evolutionarily conserved hemimethylated DNA sensor in eukaryotes. Science advances 19 39178260
2018 CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth. Haematologica 19 29880607
2019 CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion. Haematologica 18 31221787
2023 Coevolution of the CDCA7-HELLS ICF-related nucleosome remodeling complex and DNA methyltransferases. eLife 17 37769127
2021 CDCA7 Facilitates Tumor Progression by Directly Regulating CCNA2 Expression in Esophageal Squamous Cell Carcinoma. Frontiers in oncology 17 34737951
2020 LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7. Cell cycle (Georgetown, Tex.) 17 32178558
2024 CDCA7-associated global aberrant DNA hypomethylation translates to localized, tissue-specific transcriptional responses. Science advances 16 38335290
2022 CDCA7 promotes TGF-β-induced epithelial-mesenchymal transition via transcriptionally regulating Smad4/Smad7 in ESCC. Cancer science 15 36056599
2024 The C-terminal 4CXXC-type zinc finger domain of CDCA7 recognizes hemimethylated DNA and modulates activities of chromatin remodeling enzyme HELLS. Nucleic acids research 14 39142653
2021 CDCA7-regulated inflammatory mechanism through TLR4/NF-κB signaling pathway in stomach adenocarcinoma. BioFactors (Oxford, England) 14 34339079
2021 Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression. Bioengineered 14 34551671
2024 The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA. Science advances 13 39178265
2019 ZBTB24 regulates the apoptosis of human T cells via CDCA7/TRAIL-receptor axis. Biochemical and biophysical research communications 9 31030944
2025 CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance. Cell death & disease 8 39905019
2025 The ZBTB24-CDCA7-HELLS axis suppresses the totipotent 2C-like reprogramming by maintaining Dux methylation and repression. Nucleic acids research 2 40226918
2025 Major alleles of CDCA7 shape CG methylation in Arabidopsis thaliana. Nature plants 2 41203935
2025 CDCA7 facilitates MET1-mediated CG DNA methylation maintenance in centromeric heterochromatin via linker histone H1. Proceedings of the National Academy of Sciences of the United States of America 2 41370347
2023 The ICF syndrome protein CDCA7 harbors a unique DNA-binding domain that recognizes a CpG dyad in the context of a non-B DNA. bioRxiv : the preprint server for biology 2 38168392
2023 CDCA7 is a hemimethylated DNA adaptor for the nucleosome remodeler HELLS. bioRxiv : the preprint server for biology 2 38187757
2025 CircASH1L inhibits ferroptosis and enhances cisplatin resistance by sponging miR-515-5p to regulate cell cycle-related CDCA7/RRM2 in ovarian cancer cells. Frontiers in pharmacology 1 40630134
2023 Coevolution of the CDCA7-HELLS ICF-related nucleosome remodeling complex and DNA methyltransferases. bioRxiv : the preprint server for biology 1 36778482
2026 CDCA7 promotes chemoresistance of drug-tolerant persister cells in breast cancer by upregulating the expression of autophagy-related protein genes. Frontiers in immunology 0 41890763
2024 METTL3-mediated m6A modification of CDCA7 mRNA promotes COAD progression. Pathology, research and practice 0 38959625
2024 Circ_0006220 (circ-TADA2A) accelerates prostate cancer cell malignant behaviors through miR-520f-3p/CDCA7 axis. Cellular and molecular biology (Noisy-le-Grand, France) 0 39097891